Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
Reducing redundancy and duplication helps ensure that AI models are trained and operate on high-quality data, producing ...
Supply Chain Management Review, reposted here, a Rutgers Business School graduate student (Master of Supply Chain Analytics) explains how as disruptions become structural rather than episodic, ...
Automakers face higher costs from US port fees, car carrier Wallenius Wilhelmsen warns Automakers transporting their cars to the U.S. could face $200 to $300 per vehicle in additional costs, the CEO ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback